x

Cerca una sperimentazione clinica

* (*) campo obbligatorio

7 Risultato/i

Sperimentazione in fase di reclutamento = Sperimentazione in fase di reclutamento
; Sperimentazione in corso = Sperimentazione in corso
; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

FRANCIA

AUVERGNE-RHONE-ALPES
BRON

A study of the safety, efficacy, pharmacokinetics and pharmacodynamics of recombinant human alpha glucosidase (rhGAA) treatment in patients >6 m and <36 m old with infantile onset Pompe disease (Phase II) - Terminated -
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service d'endocrinologie et de diabétologie pédiatriques et maladies héréditaires du métabolisme

FRANCIA

AUVERGNE-RHONE-ALPES
BRON

A dose-ranging study of the safety, efficacy, pharmacokinetics and phamacodynamics of recombinant human Acid Alpha Glucosidase (rhGAA) treatment in patients <6 m old with infantile onset Pompe disease (Phase II) - Terminated -
CHU de Lyon HCL - GH Est-Hôpital Femme Mère Enfant
Service d'endocrinologie et de diabétologie pédiatriques et maladies héréditaires du métabolisme

FRANCIA

ILE-DE-FRANCE
PARIS

Observational Study About the Evolution of Severe Late Onset Pompe Disease Patient With Pulmonary Dysfunction and Receiving Myozyme
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière
Groupement hospitalier universitaire Pitié-Salpétrière

PAESI BASSI

Zuid-Holland
ROTTERDAM

Single-Center, Open-Label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease
Erasmus MC - Erasmus Medisch Centrum
Centrum voor Lysosomale en Metabole Ziekten